Compare GoPro Inc (GPRO) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GoPro Inc vs Moderna, Inc. — how do they compare? GoPro Inc trades at $0.67 (market cap $122.03M), while Moderna, Inc. trades at $63.97 (market cap $27.09B). The key difference: Moderna, Inc. is far larger — about 222× GoPro Inc's market cap, and Moderna, Inc. is trading nearer its 52-week high, GoPro Inc nearer its low. Which is the better fit depends on your goals.
| GPRO | MRNA | |
|---|---|---|
Market Cap | $122.03M | $27.09B |
Sector | Technology | Health |
52-Week High | $2.88 | $81.80 |
52-Week Low | $0.64 | $22.36 |
Enterprise Value | $169.98M | $23.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GoPro (GPRO) trades at $0.6732, down 3.53% on the day, reflecting persistent financial stress with a net income margin of -20.7% and negative cash flow. The company is undergoing a strategic review for potential sale or merger, announced May 11, 2026, after receiving inbound interest. Technical indicators are bearish, with moving averages signaling continued downward pressure, while recent product launches like the MISSION 1 series aim to revive growth amid declining revenues.
The outlook hinges on the strategic review outcome; a successful sale could provide shareholder value, but ongoing losses and high burn rate pose significant risks. Investors face binary event-driven speculation, with analyst consensus mixed and substantial downside if restructuring fails.
Moderna (MRNA) trades at $64.11, down 4.94% over 24 hours, with a bullish technical outlook but mixed fundamentals. The company reported a net loss of -$2.82B in 2025 despite beating EPS estimates in recent quarters. Recent news highlights progress in oncology trials and an EU RSV vaccine contract, fueling investor optimism about pipeline expansion beyond COVID-19 vaccines.
Outlook: Long-term growth depends on successful pipeline commercialization, but high cash burn and negative margins pose risks. Analyst consensus is cautious with a $49 price target, suggesting 23.6% downside. Investors should weigh clinical successes against persistent profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GoPro Inc
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts, drones and appliances. The company outsources a part of manufacturing to third parties in China. The company sells products across the world through its direct sales channel, which generates over half of total revenue, and indirectly through its distribution channel. The company has presence, including in the Americas, Europe, Middle East, Africa, and Asia-Pacific, with the Americas contributing over half of total revenue.
Read more on GPRO →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
